Considerable evidence from animal models of depression indicates that chronic stress induces synaptic dysfunction and loss
Tirzepatide, which stimulates both GLP-1 and GIP receptors, appears to have fewer side effects
And more necessary information you would expect to know
Its role in performance enhancement alone remains inconclusive, and therefore it is positioned as a complementary rather than primary performance nutrient
Increasing Investment in R&D Increasing investment in R&D is another major factor driving the growth of the GLP-1 targeted peptide weight loss drugs market, as it accelerates the development of more effective, longer-acting, and patient-friendly therapies
, 12 , 791-792, Schnherr, H., and Cernak, T